On March 28, 2024, the Qingdao High-End Intelligent Manufacturing Industrial Base for Life and Health Technology was officially launched, with a signing ceremony for the first batch of resident companies held in Qingdao's Shibei District. The event featured speeches from Jiang Baoguo, Academician of the Chinese Academy of Engineering and Director of the National Trauma Medical Center, and Geng Tao, Member of the Standing Committee of the Qingdao Municipal Party Committee and Vice Mayor. The event was attended by Bo Tao, Vice Chairman of the Qingdao CPPCC and Director of the Qingdao Municipal Health Commission, along with other key officials from relevant city and district departments, and Fu Gang, Chairman of Baheal Pharma Group. At the ceremony, four innovative companies incubated by Baheal Pharma Group signed agreements to become the first residents of the base. Additionally, the Qingdao Huizhu Baheal Medical and Health Industrial Investment Fund was officially signed.

The local government of Mentougou recently organized a prestigious recognition event, the "Mentougou Role Model - Flood Control Pioneer" awards ceremony, to honor those who showed exceptional bravery and commitment during critical flood control and emergency rescue efforts. At this high-profile gathering, the district government officially praised and designated numerous heroes from the community who made significant impacts. Notably, Baheal Pharma Group stood out among several dedicated groups and individuals, earning the distinguished "Mentougou Role Model - Flood Control Pioneer" title as an advanced collective. Deputy Secretary-General of the Beijing Municipal Government, Han Geng, Vice Minister of the Municipal Publicity Department and Director of the Capital Civilization Office, Teng Shengping, Secretary of the District Committee, Yu Huafeng, Chairman of the Standing Committee of the District People's Congress, Zhang Weigang, Deputy Secretary of the District Committee and Secretary of the Political and Legal Committee, Wang Jianhua, along with other municipal and district leaders, attended the conference.

Frost & Sullivan, a globally recognized growth consulting firm, recently unveiled the "China RADIOPharma Industry Current State and Future Development Blueprint." This detailed report offers an in-depth analysis of the Chinese nuclear medicine industry's infrastructure and growth dynamics. It highlights technological advancements, pipeline development, supportive governmental policies, market expansion, and investor interest to illustrate the sector's technological evolution and pathways. Among the spotlighted entities, RADIOPharma emerges as a notable example within the Blueprint. This innovative company, fostered by Baheal Pharma Group's investment, has earned its place through its sophisticated approach to nuclear medicine diagnostics and treatment, garnering international acclaim for its research efforts.

On November 26, a landmark partnership was cemented in the healthcare and pharmaceutical landscape, as the signing ceremony for the Baheal Pharmal Brand Commercialization North Logistics Base and the Baheal Pharma Advanced Manufacturing Industrial Base Project took place in the Linkong Economic Zone (Langfang). This pivotal event signifies a major advancement in the collaboration between Baheal Pharma Group and the Linkong Economic Zone (Langfang) to expedite the development of these key projects in Langfang. The initiative promises to elevate the regional life sciences industry and catalyze high-quality growth, injecting dynamic energy into the region's expansion efforts.

On the night of November 19, 2023, Qingdao Qingdao Baheal Medical Inc. ("Baheal Medical", 301015.SZ) announced it has entered into landmark commercialization agreements with Guangdong RADIO Pharma Technology Co., Ltd. ("Radio") and Beijing Medis Medical Technology Co., Ltd. ("Medis Medical"). With these agreements, Baheal Medical will exclusively commercialize a portfolio of radio-pharmaceuticals in mainland China, which include Radio's innovative class 1 nuclear medical oncology diagnostic drug, 99mTc-3PRGD2, along with a range of imaging products such as SPECT. In addition, Baheal Medical will also exclusively manage the commercial operations of Medis Medical’s Electromagnetic Localization Puncture Guidance Device and associated products for ultrasound applications.